EL7.AI
StocksMedium•30 March 2026•
1 min read

InflaRx Presents Phase 3 Vilobelimab Data at AAD 2026 Annual Meeting

Key Facts

1InflaRx announced the presentation of Phase 3 study data for vilobelimab in pyoderma gangrenosum (PG).
2The data was featured in a late-breaker oral presentation at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
3InflaRx (Nasdaq: IFRX) focuses on anti-inflammatory therapeutics by targeting the complement system.

InflaRx N.V. (Nasdaq: IFRX) announced the presentation of its Phase 3 clinical trial data for vilobelimab at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The data, focusing on the treatment of pyoderma gangrenosum (PG), was featured in a high-profile late-breaker oral presentation in Denver. Vilobelimab is a first-in-class monoclonal antibody designed to target the complement system to manage inflammatory conditions. This presentation marks a significant milestone for the company as it shares late-stage clinical activity and safety results with the global medical community. The successful showcase of Phase 3 results often serves as a critical step toward regulatory filings and potential commercialization. Investors are closely monitoring these developments as they validate InflaRx's therapeutic pipeline and research capabilities.